How we are engineering bacteria to eat cancer

Cancer researchers have long sought to overcome the hurdle of selectively targeting cancerous cells while sparing healthy tissue. Despite significant advancements in modern medicine, current cancer therapies often struggle with this delicate balance. According to recent studies, the majority of cancer treatments, including chemotherapy and radiation, can cause severe side effects due to their non-specific nature, which affects both malignant and non-malignant cells.

Scientists have been working to develop more precise cancer therapies, focusing on the unique genetic and molecular characteristics of cancer cells. One promising approach involves the use of immunotherapy, which harnesses the body's immune system to recognize and attack cancer cells. Another area of research has centered on targeted therapies, which aim to selectively inhibit specific molecular pathways that are overactive in cancer cells. These targeted approaches have shown promise in reducing side effects and improving treatment outcomes for certain types of cancer.

As researchers continue to explore new and innovative cancer therapies, the goal remains to develop treatments that can effectively target cancer cells while minimizing harm to healthy tissue. With ongoing advances in our understanding of cancer biology and the development of more precise therapeutic strategies, the prospect of more effective and less toxic cancer treatments becomes increasingly promising.